Cargando…
Impact of First-Line FOLFIRINOX-Induced Peripheral Neuropathy on the Efficacy of Second-Line GnP in Patients with Unresectable Advanced Pancreatic Cancer
Modified FOLFIRINOX (mFFX) and Gemcitabine plus nab-paclitaxel (GnP) are effective first-line chemotherapies for unresectable advanced pancreatic cancer (APC); however, both lead to peripheral neuropathy (PN). Aims: To evaluate the impact of first-line mFFX-induced PN on the efficacy of second-line...
Autores principales: | Sadaka, Shiori, Iwashita, Takuji, Fujii, Hironori, Kato-Hayashi, Hiroko, Ohata, Koichi, Uemura, Shinya, Shimizu, Masahito, Suzuki, Akio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9572211/ https://www.ncbi.nlm.nih.gov/pubmed/36233762 http://dx.doi.org/10.3390/jcm11195895 |
Ejemplares similares
-
Severe Neutropenia is Associated with Better Clinical Outcomes in Patients with Advanced Pancreatic Cancer Who Receive Modified FOLFIRINOX Therapy
por: Yamada, Yunami, et al.
Publicado: (2018) -
Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure
por: Mita, Naoki, et al.
Publicado: (2019) -
Anorexia, pain and peripheral neuropathy are associated with a decrease in quality of life in patients with advanced pancreatic cancer receiving outpatient chemotherapy — a retrospective observational study
por: Fujii, Hironori, et al.
Publicado: (2021) -
A multicenter prospective phase II study of first-line modified FOLFIRINOX for unresectable advanced pancreatic cancer
por: Yoshida, Kensaku, et al.
Publicado: (2017) -
Clinical Outcomes of Conversion Surgery after FOLFIRINOX in Patients with Unresectable Advanced Pancreatic Cancer: A Retrospective Cohort Study at a Single Center
por: Mita, Naoki, et al.
Publicado: (2021)